Anticoagulation is thought to be associated with the risk of intracranial hemorrhage (ICH) in patients with brain metastases; however, the data on this topic are limited. This study was conducted to determine the incidence of ICH associated with anticoagulant use in adult patients with brain metastases. Consecutive patients with brain metastases occurring from 2006 to 2014 were identified from a single-institution database. Long-term anticoagulant therapy was defined as outpatient anticoagulation therapy of > 1 month. Chi-square tests and Fisher's exact test were used to compare rates of ICH by groups. This cohort included 125 patients with brain metastases. Of these, 64 had primary of non-small cell lung cancer (51.2%). Of these patients, 12/125 (9.6%) patients developed ICH. Neither the primary tumor site nor the number of brain metastases was associated with the development of ICH. ICH incidence was not associated with the use of anticoagulant therapy, with 8/67 (11.94%) patients on outpatient anticoagulation and 4/58 (6.9%) not on anticoagulation experiencing ICH (p = 0.33). The type of treatment did not significantly influence ICH, although those having combined WBRT and SRS were numerically more likely to experience ICH (4/15; 26.67%) of this cohort. In patients on enoxaparin, there was no difference in the incidence of ICH for daily versus twice-daily dosing (p = 1.0). Long-term anticoagulant use is not associated with an increased incidence of ICH in patients with intracranial metastases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12032-018-1101-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Phase II Trial of Brain MRI Surveillance in Stage IV Breast Cancer.
Neuro Oncol
January 2025
Department of Breast Oncology, Moffitt Cancer Center.
Background: Screening of asymptomatic stage IV breast cancer with brain MRIs is currently not recommended by National Comprehensive Cancer Network (NCCN) Guidelines. The incidence of asymptomatic brain metastasis is not well documented.
Methods: The study is designed as a single arm, phase II trial, with the goal of investigating surveillance brain MRIs in neurologically asymptomatic patients with metastatic breast cancer.
Exploring the role of metabolic pathways in TNBC immunotherapy: insights from single-cell and spatial transcriptomics.
Front Endocrinol (Lausanne)
January 2025
The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China.
The article provides an overview of the current understanding of the interplay between metabolic pathways and immune function in the context of triple-negative breast cancer (TNBC). It highlights recent advancements in single-cell and spatial transcriptomics technologies, which have revolutionized the analysis of tumor heterogeneity and the immune microenvironment in TNBC. The review emphasizes the crucial role of metabolic reprogramming in modulating immune cell function, discussing how specific metabolic pathways, such as glycolysis, lipid metabolism, and amino acid metabolism, can directly impact the activity and phenotypes of various immune cell populations within the TNBC tumor microenvironment.
View Article and Find Full Text PDFImpacts of Calculation Grid Spacing and Statistical Uncertainty of Monte Carlo Algorithm on Stereotactic Radiosurgery Planning With Volumetric-Modulated Arcs for Single Brain Metastases Using the Monaco® System.
Cureus
December 2024
Department of Radiology, Aichi Medical University, Nagakute, JPN.
Purpose In linac-based stereotactic radiosurgery (SRS) utilizing a multileaf collimator (MLC) for brain metastases (BMs), a volumetric-modulated arc (VMA) technique is indispensable for generating a suitable dose distribution with efficient planning and delivery. However, the optimal calculation grid spacing (GS) and statistical uncertainty (SU) of the Monte Carlo algorithm for VMA optimization have yet to be determined. This planning study aimed to examine the impacts of GS and GU settings on VMA-based SRS planning and to find the optimal combination for templating.
View Article and Find Full Text PDFLncRNA-PVT1 enhances glucose metabolism of pediatric low-grade glioma cells through sponging miR-187-3p.
Pol J Pathol
January 2025
Department of Neonatology, Weifang Maternal and Child Health Hospital, China.
Pediatric low-grade glioma (PLGG) is a heterogeneous group of primary central nervous system malignancies which represent the most frequent brain tumors in children. Although diagnosis and treatment of PLGG have been improved recently, the molecular mechanisms underlying the oncogenesis and progression of PLGG remain elusive. Studies have revealed critical roles of long non-coding RNAs (lncRNAs) in brain tumor progressions.
View Article and Find Full Text PDFIdentification of the clinical and genetic characteristics of gliomas with gene fusions by integrated genomic and transcriptomic analysis.
Eur J Med Res
January 2025
Department of Neurosurgery, Institute of Brain Diseases, Nanfang Hospital, Southern Medical University, Guangzhou Avenue North No.1838, Guangzhou, 510515, Guangdong, People's Republic of China.
The identification of oncogenic gene fusions in diffuse gliomas may serve as potential therapeutic targets and prognostic indicators, representing a novel strategy for treating gliomas consistent with the principles of personalized medicine. This study identified detectable oncogene fusions in glioma patients through an integrated analysis of genomic and transcriptomic data, which encompassed whole exon sequencing and next-generation RNA sequencing. In addition, this study also conducted a comparison of the genetic characteristics, tumor microenvironment, mutation burden and survival between glioma patients with or without gene fusions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!